Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: Nov 7, 2025

Lasme-cel in r/r B-ALL (BALLI-01)

Eti-cel in r/r NHL (NATHALI-01)

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the third quarter 2025 ending September 30, 2025 and business updates.